Network pharmacology research showed that FZLZD mainly reduces the expression of proteins such as PTPN1, EGFR, and IL6 by affecting cell signal transduction pathways and protein phosphorylation modifications, thereby delaying tumor cell proliferation, promoting tumor cell death, synergistically enhancing the efficacy of XELOX plus sintilimab regimen in the treatment of advanced GC, and ultimately improving patient quality of life. This evidence concerns the gene EGFR and neoplasm.